Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237940 | 0.95 | PDE3B (0.34) | KDM4EMEN1ALDH1A1KMT2APTGDR2 | |
| SCHEMBL10237945 | 0.87 | SLC6A3 (0.37) | KDM4EMEN1ALDH1A1KMT2APDE3B | |
| SCHEMBL10237956 | 0.86 | CYP11B1 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL10237901 | 0.82 | PDE3B (0.34) | MEN1KMT2APDE3BPDE3ACNR2 | |
| SCHEMBL10238143 | 0.82 | EIF4E (0.34) | KDM4EALDH1A1 | |
| SCHEMBL16215992 | 0.81 | HRH3 (0.41) | KDM4EMEN1ALDH1A1KMT2APTGDR2 | |
| SCHEMBL10237937 | 0.81 | HRH3 (0.41) | KDM4EMEN1ALDH1A1KMT2APTGDR2 | |
| SCHEMBL608047 | 0.81 | HRH3 (0.41) | KDM4EMEN1ALDH1A1KMT2APTGDR2 | |
| SCHEMBL10238014 | 0.80 | GLA (0.36) | KDM4EALDH1A1PTGDR2GLA | |
| SCHEMBL10237996 | 0.80 | KDM4E (0.40) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176222-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040826-A1 | NOVEL HERBICIDES | DDT, HDHD5, DDC | KDM4E 1609/4885MEN1 4762/4885ALDH1A1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.